Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care

2343 - Benefit of adjuvant chemotherapy in hormone receptor-positive, HER2-negative, invasive lobular carcinoma of the breast

Date

22 Oct 2018

Session

Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care

Presenters

Alexandre De Nonneville

Citation

Annals of Oncology (2018) 29 (suppl_8): viii58-viii86. 10.1093/annonc/mdy270

Authors

A. De Nonneville1, C. Jauffret2, A. Gonçalves1, J. Classe3, M. Cohen4, F. Reyal5, C. Mazouni6, M. Chauvet7, N. Chopin8, P. Colombo9, E. Jouve10, E. Darai11, R. Rouzier12, C. Coutant13, P. Gimbergues14, A. Azuar15, C. Tunon de Lara16, E. Lambaudie4, G. Houvenaeghel4

Author affiliations

  • 1 Department Of Medical Oncology, Institute Paoli Calmettes, 13274 - Marseille/FR
  • 2 Department Of Surgical oncology, Institute Paoli Calmettes, 13274 - Marseille/FR
  • 3 Department Of Surgical oncology, ICO Institut de Cancerologie de l'Ouest René Gauducheau, 44805 - Saint-Herblain/FR
  • 4 Department Of Surgical oncology, Institute Paoli Calmettes, 13009 - Marseille/FR
  • 5 Department Of Surgical oncology, Institut Curie, Paris/FR
  • 6 Department Of Surgical oncology, Institut Gustave Roussy, Villejuif/FR
  • 7 Department Of Surgical oncology, Centre Oscar Lambret, Lille/FR
  • 8 Department Of Surgical oncology, Centre Leon Berard, Lyon/FR
  • 9 Department Of Surgical oncology, CLCC Val d'Aurelle, Montpellier/FR
  • 10 Department Of Surgical oncology, Centre Claudius Regaud, Toulouse/FR
  • 11 Department Of Gynecologic And Breast Cancers, Hôpital Tenon, Paris/FR
  • 12 Surgery, Institut Curie, 75248 cedex5 - Paris/FR
  • 13 Department Of Surgical oncology, Centre Georges-François Leclerc (Dijon), 21000 - Dijon/FR
  • 14 Department Of Surgical oncology, Centre Jean-Perrin, Clermont-Ferrand/FR
  • 15 Department Of Surgical oncology, Hôpital de Grasse, Grasse/FR
  • 16 Department Of Surgical oncology, Institut Bergonié, Bordaux/FR
More

Resources

Abstract 2343

Background

Invasive lobular carcinoma (ILC) is the second most common histologic breast cancer subtype and represent approximately 10% of all breast cancers. Despite this high frequency, benefit of adjuvant chemotherapy (CT) in ILC is still unclear.

Methods

Our objective was to investigate the impact of CT on survival in ILC. Patients were retrospectively identified from a cohort of 23,537 patients who underwent primary surgery in 18 French centres between 1990 and 2014. Only ILC, hormone-positive, HER2-negative patients who received adjuvant endocrine therapy (ET) were included. Endpoints were disease-free survival (DFS) and overall survival (OS). A propensity score for receiving CT was estimated using a logistic regression including age, tumour size, nodal status, lymphovascular invasion (LVI), grade, type of surgery, period and CT.

Results

Of a total of 2,318 patients with ILC, 1,485 patients (64%) received ET alone and 823 (36%) received ET+CT. Patients receiving ET+CT had more adverse prognostic features, such as young age, larger tumour size, high grade, macroscopic lymph-node involvement and LVI, received more adjuvant radiotherapy and underwent more often mastectomy. In a multivariate Cox model, we observed a beneficial effect of addition of CT to ET on both DFS and OS, (HR = 0.61, 95% CI [0.41-0.90]; p = 0.01 and 0.52, 95% CI [0.31-0.87]; p = 0.01, respectively). This effect was even more pronounced when propensity score-matching, aiming to compensate for baseline characteristics, was used. Ten-year estimates DFS in case-matched patients for propensity score analysis were 90% (95% CI [87%-93.4%]) in the ET+CT group vs. 66% (95% CI [61.4%-71.4%]) with ET alone and 10-year estimates OS were 96% (95% CI [93.8%-98%]) in the ET+CT group vs. 71% (95% CI [66.6% et 76.2%]) with ET alone. Regarding subgroup analysis, low-risk patients without CT did not have significant differences in DFS or OS compared to low-risk patients with CT.

Conclusions

Patients receiving adjuvant ET for hormone receptor-positive, HER2-negative ILC could derive significant DFS and OS benefits from CT. Our results highlight that patients with high-risk ILC should not be denied adjuvant CT because of such histologic subtype.

Clinical trial identification

Legal entity responsible for the study

Gilles Houvenaeghel.

Funding

Has not received any funding.

Editorial Acknowledgement

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings